Search
Gabapentin enacarbil
go.drugbank.com/drugs/DB08872ApprovedGabapentin enacarbil is marketed under the name Horizant. It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).
Sodium lauryl sulfoacetate
go.drugbank.com/drugs/DB13157ApprovedWithdrawnSodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products.
Synonyms: Sulfoacetic acid dodecyl ester S-sodium saltBenzgalantamine
go.drugbank.com/drugs/DB19353ApprovedInvestigationalBenzgalantamine is a prodrug of [galantamine]. … [L51564] Benzgalantamine was approved by the FDA in July 2024 for the treatment of mild-to-moderate dementia in Alzheimer's patients.[L51534,L51564]
Synonyms: 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, benzoate (ester), (4as,6r,8as)-Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesQuinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnIt is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand name Norprolac contained as a racemate. … Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States.
Synonyms: (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamideCategories: Heterocyclic Compounds, 2-RingPerfluorohexyloctane
go.drugbank.com/drugs/DB17823ApprovedInvestigational[A259746, A259751] Perfluorohexyloctane has been used in the field of ophthalmology as a vitreous substitute. … [A259746] Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative.
Synonyms: 1-(perfluorohexyl)octaneFluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawn[DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965]. … Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358,F4361,F4364][FDA Label].
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: ฟลิโซไทด์ เน็บบิวส์ (2 มก.)Revumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigational[L51888] In October of 20225, it was approved for myeloid leukemia patients with nucleophosmin 1 (NPM1) mutations. [L54376] … Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in
Categories: MATE 1 Inhibitors, MATE 1 SubstratesSynonyms: Benzamide, n-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-Efbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigationalThis approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887] … Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration
Synonyms: Rh g-csf fc fusion protein f-627, Recombinant dimeric g-csf fusion protein f627rsPSMA Vaccine
go.drugbank.com/drugs/DB06361ApprovedWithdrawnrsPSMA Vaccine is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003). … Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases.
Technetium Tc-99m tilmanocept
go.drugbank.com/drugs/DB09266ApprovedOnce reconstituted and labelled, technetium Tc99m tilmanocept is intended to be injected in close proximity to the tumor being diagnosed and employed in preoperative gamma detection imaging in combination … However, as nodal micrometastasis in breast cancer may not be associated with significant changes in survival, it is also important to identify clinically node-negative patients [A32170].